SCHEMBL3831476

SCHEMBL3831476

CC(C)N(C)c1nc2ccc(NC(=O)C3CCN(c4ccccc4)CC3)cc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 8/20 0.54
MAPT P10636 4/20 0.49
MALT1 Q9UDY8 1/20 0.49
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
TRPV1 Q8NER1 1/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
ME3 Q16798 1/20 0.45
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PDPK1 O15530 1/20 0.45
NR2E3 Q9Y5X4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3837985 0.91 MCHR1 (0.59) MCHR1MAPTMALT1LMNAPOLB
SCHEMBL3840767 0.85 MCHR1 (0.55) MCHR1MAPTLMNAPOLBKMT2A
SCHEMBL3832829 0.77 MCHR1 (0.59) MCHR1MAPTLMNAKMT2AMEN1
SCHEMBL3835966 0.76 MCHR1 (0.59) MCHR1MAPTPOLBNPC1ALDH1A1
SCHEMBL13818008 0.72 MCHR1 (0.81) MCHR1MAPTLMNAPOLBKDM4E
SCHEMBL3831961 0.72 MCHR1 (0.54) MCHR1MAPTKDM4ENPC1ALDH1A1
SCHEMBL3837599 0.71 MCHR1 (0.57) MCHR1MAPTKDM4ENPC1ALDH1A1
SCHEMBL3834768 0.70 MCHR1 (0.83) MCHR1MAPTLMNAPOLBKDM4E
SCHEMBL3837219 0.70 MCHR1 (0.71) MCHR1MAPTPOLBKDM4ENPC1
SCHEMBL13818000 0.70 MCHR1 (1.00) MCHR1MAPTLMNAPOLBTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1553089-B1 ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT BANYU PHARMA CO LTD (JP) 2009-09-30 EP disclosed
US-7541477-B2 Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-06-02 US disclosed
US-7541477-B2 Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-06-02 US disclosed
US-7541477-B2 Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-06-02 US disclosed
US-20050222161-A1 Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient BANYU PHARMACEUTICAL CO., LTD (JP) 2005-10-06 US disclosed
EP-1553089-A1 ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222161-A1 Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient MC1R, MCHR1, MCHR2 MCHR1 2/4885MAPT 2630/4885MALT1 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.